NCT03192943View on ClinicalTrials.gov

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

December 11, 2018

Study Completion Date

December 11, 2018

Conditions
Advanced Cancer
Interventions
DRUG

BMS-986205

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified day

Trial Locations (1)

1040045

Local Institution, Chuo-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY